查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813870

美國多體學市場規模、佔有率和趨勢分析報告：按產品/服務、類型、平台、應用、最終用途和細分市場預測，2025 年至 2033 年

U.S. Multiomics Market Size, Share & Trends Analysis Report By Product & Service (Instruments, Consumables), By Type (Single-cell, Bulk), By Platform, By Application, By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

美國多組體學市場摘要

預計 2024 年美國多組體學市場價值將達到 11.8 億美元，到 2033 年將達到 43.6 億美元，2025 年至 2033 年的複合年成長率為 15.58%。

這一顯著成長是由個人化醫療需求的不斷成長、人工智慧和機器學習在生物數據解讀中的整合以及對全面疾病分析日益成長的需求所推動的。此外，政府和私營部門對研發的投資不斷增加以及在藥物發現、診斷和精準醫療領域的應用不斷擴大預計將在預測期內進一步推動市場成長。

技術創新

體學平台和分析工具的快速技術創新是美國多體學產業的主要驅動力。高通量定序技術（例如次世代定序(NGS)）的突破，顯著提高了基因組和轉錄組資料產生的速度和深度，同時降低了每個樣本的成本。同樣，質譜、層析法和成像技術的進步也顯著提高了蛋白質體學和代謝體學研究的解析度和靈敏度。這些技術創新使研究人員能夠更詳細、更準確地了解複雜的生物過程，這對於疾病研究、藥物研發和精準診斷的應用至關重要。

強大的運算工具、雲端基礎平台和人工智慧主導的分析技術的進步徹底改變了多組體學資料的處理、整合和解讀方式。這些技術能夠無縫分析大型多層資料集，減少資料處理瓶頸，並加速洞察。因此，多組體學工作流程變得更加自動化、可擴展、經濟高效，並且越來越容易被大型製藥公司、中小型生物技術公司、學術機構和臨床實驗室所接受。這些技術進步的融合不僅將多體學的應用擴展到新的疾病領域，而且還透過普及多體學研究的途徑加速了美國市場的成長。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 產業分析工具
    • 波特五力分析
    • PESTEL分析

第4章美國多組體學市場：產品與服務的商業分析

  • 細分儀表板
  • 美國多組體學市場產品與服務波動分析
  • 美國多組體學市場規模和趨勢分析（按產品/服務，2021-2033 年）
  • 產品
  • 服務

第5章美國多組體學市場：類型業務分析

  • 細分儀表板
  • 美國多體學市場類型波動分析
  • 美國多組體學市場規模及趨勢分析（按類型）（2021-2033）
  • 單細胞多組體學
  • 批量體學

第6章美國多組體學市場：平台業務分析

  • 細分儀表板
  • 美國多體學市場平台波動分析
  • 美國多體學市場規模與趨勢分析（按平台，2021-2033）
  • 基因組學
  • 轉錄組學
  • 蛋白質體學
  • 代謝體學
  • 整合組體學平台

第7章美國多組體學市場：應用業務分析

  • 細分儀表板
  • 美國多組體學市場使用變化分析
  • 美國多體學市場規模與趨勢分析（按應用，2021-2033）
  • 細胞生物學
  • 腫瘤學
  • 神經病學
  • 免疫學

第8章美國多組體學市場：最終用途業務分析

  • 細分儀表板
  • 美國多組體學市場最終用途差異分析
  • 美國多體學市場規模和趨勢分析（按最終用途）（2021-2033）
  • 學術研究機構
  • 製藥和生物技術公司
  • 其他

第9章 競爭態勢

  • 參與企業
  • 戰略地圖
  • 2024年企業市場分析
  • 參與企業概況
    • BD
    • Thermo Fisher Scientific Inc.
    • Illumina, Inc
    • Danaher（Beckman Coulter）
    • PerkinElmer Inc.
    • Shimadzu Corporation
    • Bruker
    • QIAGEN
    • Agilent Technologies, Inc.
    • BGI Genomics
Product Code: GVR-4-68040-282-8

U.S. Multiomics Market Summary

The U.S. multiomics market size was estimated at USD 1.18 billion in 2024 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 15.58% from 2025 to 2033. This significant growth is driven by increasing demand for personalized medicine, the integration of artificial intelligence and machine learning in biological data interpretation, and the growing need for comprehensive disease profiling. Moreover, rising investments in research and development by both the government and private sectors and expanding applications in drug discovery, diagnostics, and precision healthcare are expected to propel market growth further over the forecast period.

Technological Innovations

The rapid pace of technological innovation across omics platforms and analytical tools is the key driver in the U.S. multiomics industry. Breakthroughs in high-throughput sequencing technologies, such as next-generation sequencing (NGS), have dramatically increased the speed and depth of genomic and transcriptomic data generation while reducing the cost per sample. Similarly, advancements in mass spectrometry, chromatography, and imaging technologies have significantly improved the resolution and sensitivity of proteomics and metabolomics studies. These innovations enable researchers to obtain a more detailed and accurate view of complex biological processes, essential for applications in disease research, drug discovery, and precision diagnostics.

The evolution of powerful computational tools, cloud-based platforms, and AI-driven analytics has revolutionized how multiomics data is processed, integrated, and interpreted. These technologies allow for the seamless analysis of large-scale, multi-layered datasets, reducing bottlenecks in data handling and accelerating insights. As a result, multiomics workflows are becoming more automated, scalable, and cost-effective, making them increasingly accessible to large pharmaceutical companies and smaller biotech firms, academic institutions, and clinical laboratories. The convergence of these technological advancements is not only expanding the application of multiomics across new disease areas. Still, it is also helping to democratize access to multiomics research, thereby accelerating the market's growth in the U.S.

U.S. Multiomics Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. multiomics market report based on product & service, type, platform, application, and end use:

  • Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
  • Products
    • Instruments
    • Consumables
    • Software
  • Services
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Single-cell Multiomics
  • Bulk Multiomics
  • Platform Outlook (Revenue, USD Million, 2021 - 2033)
  • Genomics
  • Transcriptomics
  • Proteomics
  • Metabolomics
  • Integrated Omics Platforms
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell Biology
  • Oncology
  • Neurology
  • Immunology
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Academic and Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product & Service
    • 1.2.2. Type
    • 1.2.3. Platform
    • 1.2.4. Application
    • 1.2.5. End Use
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological Innovation
      • 3.2.1.2. Advancements in precision medicine
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Data integration and analytical complexity
      • 3.2.2.2. High cost of multiomics technologies and workflows
  • 3.3. Industry Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis

Chapter 4. U.S. Multiomics Market: Product & Service Business Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Multiomics Market Product & Service Movement Analysis
  • 4.3. U.S. Multiomics Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
  • 4.4. Product
    • 4.4.1. Product Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.2. Instruments
      • 4.4.2.1. Instruments Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.3. Consumables
      • 4.4.3.1. Consumables Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.4. Software
      • 4.4.4.1. Software Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Services
    • 4.5.1. Services Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. U.S. Multiomics Market: Type Business Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Multiomics Market Type Movement Analysis
  • 5.3. U.S. Multiomics Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Single-cell Multiomics
    • 5.4.1. Single-cell Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Bulk Multiomics
    • 5.5.1. Bulk. Multiomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. U.S. Multiomics Market: Platform Business Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Multiomics Market Platform Movement Analysis
  • 6.3. U.S. Multiomics Market Size & Trend Analysis, by Platform, 2021 to 2033 (USD Million)
  • 6.4. Genomics
    • 6.4.1. Genomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Transcriptomics
    • 6.5.1. Transcriptomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Proteomics
    • 6.6.1. Proteomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Metabolomics
    • 6.7.1. Metabolomics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Integrated Omics Platforms
    • 6.8.1. Integrated Omics Platforms Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. U.S. Multiomics Market: Application Business Analysis

  • 7.1. Segment Dashboard
  • 7.2. U.S. Multiomics Market Application Movement Analysis
  • 7.3. U.S. Multiomics Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
  • 7.4. Cell Biology
    • 7.4.1. Cell Biology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Oncology
    • 7.5.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Neurology
    • 7.6.1. Neurology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Immunology
    • 7.7.1. Immunology Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. U.S. Multiomics Market: End Use Business Analysis

  • 8.1. Segment Dashboard
  • 8.2. U.S. Multiomics Market End Use Movement Analysis
  • 8.3. U.S. Multiomics Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
  • 8.4. Academic and Research Institutes
    • 8.4.1. Academic and Research Institutes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Pharmaceutical & Biotechnology Companies
    • 8.5.1. Pharmaceutical & Biotechnology Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Categorization
  • 9.2. Strategy Mapping
  • 9.3. Company Market Position Analysis, 2024
  • 9.4. Participant's Overview
    • 9.4.1. BD
      • 9.4.1.1. Overview
      • 9.4.1.2. Financial Performance
      • 9.4.1.3. Product Benchmarking
      • 9.4.1.4. Strategic Initiatives
    • 9.4.2. Thermo Fisher Scientific Inc.
      • 9.4.2.1. Overview
      • 9.4.2.2. Financial Performance
      • 9.4.2.3. Product Benchmarking
      • 9.4.2.4. Strategic Initiatives
    • 9.4.3. Illumina, Inc
      • 9.4.3.1. Overview
      • 9.4.3.2. Financial Performance
      • 9.4.3.3. Product Benchmarking
      • 9.4.3.4. Strategic Initiatives
    • 9.4.4. Danaher (Beckman Coulter)
      • 9.4.4.1. Overview
      • 9.4.4.2. Financial Performance
      • 9.4.4.3. Product Benchmarking
      • 9.4.4.4. Strategic Initiatives
    • 9.4.5. PerkinElmer Inc.
      • 9.4.5.1. Overview
      • 9.4.5.2. Financial Performance
      • 9.4.5.3. Product Benchmarking
      • 9.4.5.4. Strategic Initiatives
    • 9.4.6. Shimadzu Corporation
      • 9.4.6.1. Overview
      • 9.4.6.2. Financial Performance
      • 9.4.6.3. Product Benchmarking
      • 9.4.6.4. Strategic Initiatives
    • 9.4.7. Bruker
      • 9.4.7.1. Overview
      • 9.4.7.2. Financial Performance
      • 9.4.7.3. Product Benchmarking
      • 9.4.7.4. Strategic Initiatives
    • 9.4.8. QIAGEN
      • 9.4.8.1. Overview
      • 9.4.8.2. Financial Performance
      • 9.4.8.3. Product Benchmarking
      • 9.4.8.4. Strategic Initiatives
    • 9.4.9. Agilent Technologies, Inc.
      • 9.4.9.1. Overview
      • 9.4.9.2. Financial Performance
      • 9.4.9.3. Product Benchmarking
      • 9.4.9.4. Strategic Initiatives
    • 9.4.10. BGI Genomics
      • 9.4.10.1. Overview
      • 9.4.10.2. Financial Performance
      • 9.4.10.3. Product Benchmarking
      • 9.4.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. multiomics market, by product & service, 2021 - 2033 (USD Million)
  • Table 4 U.S. multiomics market, by type, 2021 - 2033 (USD Million)
  • Table 5 U.S. multiomics market, by platform, 2021 - 2033 (USD Million)
  • Table 6 U.S. multiomics market, by application, 2021 - 2033 (USD Million)
  • Table 7 U.S. multiomics market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Multiomics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market outlook
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Parent market outlook
  • Fig. 13 U.S. multiomics market driver analysis
  • Fig. 14 U.S. multiomics market restraint analysis
  • Fig. 15 U.S. multiomics market: Porter's analysis
  • Fig. 16 U.S. multiomics market: PESTEL analysis
  • Fig. 17 U.S. multiomics market: Product & service outlook and key takeaways
  • Fig. 18 U.S. multiomics market: Product & service market share analysis, 2024 - 2033
  • Fig. 19 U.S. multiomics by products market, 2021 - 2033 (USD Million)
  • Fig. 20 U.S. multiomics by instruments market, 2021 - 2033 (USD Million)
  • Fig. 21 U.S. multiomics by consumables market, 2021 - 2033 (USD Million)
  • Fig. 22 U.S. multiomics by software market, 2021 - 2033 (USD Million)
  • Fig. 23 U.S. multiomics by services market, 2021 - 2033 (USD Million)
  • Fig. 24 U.S. Multiomics market: Type outlook and key takeaways
  • Fig. 25 U.S. Multiomics market: Type market share analysis, 2024 - 2033
  • Fig. 26 U.S. multiomics by single-cell multiomics market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. multiomics by bulk multiomics market, 2021 - 2033 (USD Million)
  • Fig. 28 U.S. Multiomics market: Platform outlook and key takeaways
  • Fig. 29 U.S. Multiomics market: Platform market share analysis, 2024 - 2033
  • Fig. 30 U.S. multiomics by genomics market, 2021 - 2033 (USD Million)
  • Fig. 31 U.S. multiomics by transcriptomics market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. multiomics by proteomics market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. multiomics by metabolomics market, 2021 - 2033 (USD Million)
  • Fig. 34 U.S. multiomics by integrated omics platforms market, 2021 - 2033 (USD Million)
  • Fig. 35 U.S. Multiomics market: Application outlook and key takeaways
  • Fig. 36 U.S. Multiomics market: Application market share analysis, 2024 - 2033
  • Fig. 37 U.S. multiomics by cell biology market, 2021 - 2033 (USD Million)
  • Fig. 38 U.S. multiomics by oncology market, 2021 - 2033 (USD Million)
  • Fig. 39 U.S. multiomics by neurology market, 2021 - 2033 (USD Million)
  • Fig. 40 U.S. multiomics by immunology market, 2021 - 2033 (USD Million)
  • Fig. 41 U.S. Multiomics market: End use outlook and key takeaways
  • Fig. 42 U.S. Multiomics market: End use market share analysis, 2024 - 2033
  • Fig. 43 U.S. multiomics by academic and research institutes market, 2021 - 2033 (USD Million)
  • Fig. 44 U.S. multiomics by pharmaceutical & biotechnology companies market, 2021 - 2033 (USD Million)
  • Fig. 45 U.S. multiomics by others market, 2021 - 2033 (USD Million)
  • Fig. 46 Key company categorization
  • Fig. 47 Company market positioning
  • Fig. 48 Market participant categorization
  • Fig. 49 Strategy framework